Akili surges as video game shows improvement in adolescent ADHD patient trial

Akili

31/05/2023 13:21

** Akili Inc's shares  AKLI.O  rise 9.82% to $1.23 premarket
    ** Says its video game treatment EndeavorRx showed
improvement in adolescents aged 13-17 years with
attention-deficit/hyperactivity disorder (ADHD) in a pivotal
trial
    ** Nearly two-thirds of the 162 adolescents met the
pre-specified benchmark for improvement in assessment score of
their attention
    ** EndeavorRx is already authorized by FDA for 8-12 year
olds
    ** Three of the five brokerages covering the stock rate it
"buy", two "hold"; their median PT is $3.50 - Refinitiv data
    ** Up to Tuesday's close, stock had risen nearly 17% YTD

 (Reporting by Leroy Dsouza)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))